We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The European Medicines Evaluation Agency (EMEA) has approved the launch of Phase I clinical trials for Israel-based Kamada's alpha 1-proteinase inhibitor (API) inhaler.
King Pharmaceuticals and Wyeth Pharmaceuticals have entered into an amended and restated co-promotion agreement regarding King's product Altace (ramipril), an angiotensin converting enzyme (ACE) inhibitor.
Cardinal Health has signed agreements to manufacture and package Tamiflu for Swiss drugmaker Roche to help meet current and future demands for the influenza medicine, which is recommended by the World Health Organization (WHO) as a frontline treatment against a potential pandemic avian flu outbreak.
S*BIO has taken a significant step forward in its drug discovery and development efforts as its lead clinical candidate for cancer moves toward clinical trials.
Serving growing markets with ALTANA's strategically important products ALTANA Pharma, the pharmaceutical division of ALTANA AG today performed the official opening of a new tablet production facility in Cork (Ireland) in the presence of the Irish Prime Minister, Mr. Bertie Ahern.
Barr Pharmaceuticals, Inc. today said that it has made its required filings with the U.S. Federal Trade Commission (FTC), German regulators and all other regulatory filings regarding its proposed acquisition of Zagreb, Croatia-based PLIVA d.d.
Asterand plc, the human tissue research company, announced that it had entered into agreements with Mitsui Corporation and Toyobo Co. Ltd., to offer drug discovery services to the Japanese market.
Solstice Neurosciences Inc. has reached an Exclusive License Agreement with DreamPharma Corporation of Seoul, Korea, to evaluate and develop cosmetic and therapeutic uses of Myobloc (Botulinum Toxin Type B) Injectable Solution for a range of specialty biopharmaceutical products in Korean markets.
Chinese pharmaceutical company, China Biopharmaceuticals Holdings Inc. (CHBP) has completed the acquisition of all of the shares in RACP Pharmaceutical Holdings Ltd., and its wholly owned subsidiaries, including Shenyang Enshi Pharmaceutical Co. Ltd. from RimAsia Capital Partners LP.